全球罕见血友病因素市场 – 行业趋势和 2029 年预测

市场分析和规模

未来几年，罕见血友病因素领域预计将以健康的速度增长。随着骨髓瘤、贫血、镰状细胞性贫血和白血病等多种血液相关疾病的发病率不断上升，血液学家越来越关注各种发现过程。与精确的诊断程序相比，血液学家更喜欢改进的治疗过程。

Data Bridge Market Research 分析，罕见血友病因素市场在 2021 年为 788.3 亿美元，到 2029 年将飙升至 1265.9 亿美元，预计在 2022 年至 2029 年的预测期内复合年增长率为 6.10%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

市场定义

Hemophilia is an uncommon disorder in which the blood does not clot properly due to a deficiency in blood-clotting proteins (clotting factors). If you have haemophilia, you may bleed for longer periods of time following an accident than if your blood clots normally. Small cuts are usually not a big deal.

Rare Hemophilia Factors Market Dynamics

Drivers

• New technological advancements

Several concentrations have recently acquired marketing permission from regulatory organisations. Coagadex, for example, was approved by the FDA in October 2015 for the treatment of hereditary factor X deficiency. In 2011, the FDA approved CSL Behring's product Corifact for the treatment of congenital factor XIII (FXIII) deficiency. The introduction of new items is anticipated to boost the market. Patients will be more aware of innovative concentrations if they are more widely available. They will also have more therapy options.

• Rising adoption of prophylactic treatments

Patients' increasing use of preventative therapies is also contributing to the market's rise. Prophylaxis has a number of advantages, including a lower risk of joint pain and damage. Prophylactic medication is indicated for patients with severe uncommon haemophilia disorders to prevent bleeding episodes and improve quality of life. For example, both adult and paediatric patients with congenital factor XIII A-subunit deficiency should receive long-term preventive treatment with NovoThirteen (rFXIII-A). Continuous treatment improves the efficacy and performance of prophylaxis, resulting in a higher adoption rate. As a result, market growth is expected to accelerate throughout the forecast period.

• Research and development activities

Attempts by the International Rare Disorders Research Consortium (IRDiRC) in Europe to create 200 novel medicines for such diseases by 2020, as well as funding for studies and R&D activities, are likely to boost the market for haemophilia factors. Furthermore, actions conducted by patient advocacy groups, academic institutions, other nonprofit organisations, and pharmaceutical businesses drives regional markets.

Opportunities

Patients and practitioners are becoming more aware of the rare haemophilia coagulation diseases due to government initiatives and mandates, which has increased diagnostic and treatment rates for this condition. As a result, the market's growth is expected to accelerate throughout the forecast period. For example, the United States Congress passed the Orphan Drug Act (ODA) in 1983. Between 1983 and 2015, around 3,647 medicines were designated as orphan medications, with the FDA approving 554 of them. These orphan drug approvals have resulted in better treatment options for people suffering from uncommon diseases such rare haemophilia disorders.

Restraints/Challenges

Increased risk of joint damage, increased risk of spontaneous bleeds, causes problems with blood clotting, these are some factors which will hamper the growth of the rare hemophilia factors market in the forecast period.

This rare hemophilia factors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rare hemophilia factors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Rare Hemophilia Factors Market Scope

The rare hemophilia factors market is segmented on the basis of type, treatment. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Factor I
• Factor II
• Factor V
• Factor VII
• Factor X
• Factor XI
• Factor XIII

Treatment

• Factor Concentrates
• Fresh Frozen Plasma
• Cryoprecipitate
• Others

Rare Hemophilia Factors Market Regional Analysis/Insights

The rare hemophilia factors market is analysed and market size insights and trends are provided by country, type, treatment as referenced above.

The countries covered in the rare hemophilia factors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, sEgypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to government initiatives to upsurge the rate of diagnosis and reduce treatment costs and research activities to improve management of rare hemophilia conditions.

Asia-Pacific is expected to witness the highest growth over the forecast period owing to the growing population and increasing incidence of autosomal recessive disorders.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和罕见血友病因素市场份额分析

罕见血友病因素市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对罕见血友病因素市场的关注有关。

罕见血友病因素市场的一些主要参与者包括：

• 百特（美国）
• 拜耳公司（德国）
• 生物产品实验室有限公司（英国）
• Biogen（美国）
• 中超联赛（美国）
• 诺和诺德公司（丹麦）
• 辉瑞公司（美国）
• 武田药品工业株式会社（日本）
• Alexion Pharmaceuticals, Inc（美国）
• Shire plc（美国）
• ICON plc (美国)
• 安进公司 (美国)
• BioMarin (美国)

SKU-68622